# How Retatrutide Works: The Triple-Agonist Mechanism > How retatrutide works — its triple-agonist mechanism at GLP-1, GIP, and glucagon receptors, the cryo-EM structural data, and how the three pathways combine to produce weight loss and liver-fat reduction. A single 39-amino-acid peptide. Three hormone receptors. A mechanistic explanation of why the combination drives larger metabolic effects than its predecessors. ## The brief version Understanding how retatrutide works starts with the problem it is engineered to solve. Earlier anti-obesity compounds activated one receptor at a time. Retatrutide activates three simultaneously — GLP-1, GIP, and glucagon — using a single engineered peptide molecule. Think of the three receptors as three levers: GLP-1 turns down appetite (you want to eat less), GIP improves how your body handles blood sugar after meals (the pancreas responds better), and glucagon turns up the body's calorie-burning rate (you burn more even at rest). Together, the three effects drive weight loss that Phase 2 trials found larger than any single-lever or two-lever approach. The liver-MASLD finding is specifically linked to the glucagon lever: glucagon receptor activation drives the breakdown of fat stored in liver cells — a mechanism that GLP-1–only drugs achieve only indirectly, through weight loss. This is why retatrutide produced −82.4% liver-fat reduction in a dedicated MASLD trial, versus more modest figures for GLP-1–only agents [5]. ## GLP-1 receptor arm: appetite and glucose control GLP-1 (glucagon-like peptide-1) is a gut-derived incretin hormone — a hormone released by the intestine after eating that signals the brain and pancreas to regulate glucose and appetite. GLP-1 receptor (GLP-1R) activation in the hypothalamus (the brain's hunger-regulation center) suppresses appetite and reduces food intake. It also slows gastric emptying — food moves through the stomach more slowly, extending the physical sensation of fullness. Glucose-dependent insulin secretion is a key safety feature of this arm: retatrutide's GLP-1 agonism stimulates insulin release only when blood glucose is elevated, which reduces hypoglycemia risk compared with older insulin-secretagogues that operate independently of glucose levels. Retatrutide's relative potency at GLP-1R is approximately 0.4× that of native GLP-1, as measured in receptor binding and cAMP (cyclic adenosine monophosphate — the intracellular second messenger these receptors use) signaling assays confirmed by cryo-EM structural work [3]. This is deliberate calibration: the GIP and glucagon arms carry more of the weight, with GLP-1 providing glucose-dependent insulin benefit and appetite suppression without dominating the potency balance. ## GIP receptor arm: insulinotropic and adipose effects GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone. Like GLP-1, GIP is released after eating and stimulates insulin secretion from the pancreas — the two incretin hormones together account for the majority of post-meal insulin response in healthy individuals. The GIP receptor (GIPR) also has direct effects on adipose (fat) tissue, influencing fat cell metabolism and storage. Retatrutide's relative potency at GIPR is approximately 8.9× native GIP [3] — the most potent arm of the three. This high GIPR potency reflects a design choice: enhanced GIP signaling appears synergistic with GLP-1 activation, producing larger appetite and insulin effects in combination than either achieves alone. The mechanisms are complementary because the two incretin pathways engage overlapping but distinct downstream signaling cascades. The clinical relevance is visible in the trial data: retatrutide's Phase 2 weight-loss figures (−24.2% at 48 weeks) exceed those of GLP-1–only agents, and the additional incretin engagement from GIP is a plausible contributor alongside the glucagon energy-expenditure effect [1, 6]. ## Glucagon receptor arm: energy expenditure and liver fat Glucagon is a pancreatic hormone best known for raising blood glucose (opposing insulin). But glucagon receptor (GCGR) activation also increases energy expenditure — the body burns more calories at rest — and drives hepatic lipolysis (breakdown of fat stored in liver cells) and mitochondrial fat oxidation in the liver. This hepatic pathway is the mechanism most directly relevant to the liver-MASLD findings. The liver accumulates excess fat (hepatic steatosis — the defining feature of MASLD) when energy intake persistently exceeds expenditure and when hepatic lipid export is overwhelmed. Glucagon receptor activation accelerates the clearance of that stored fat via direct hepatic oxidative pathways, independently of the weight-loss-mediated route that GLP-1–only agents primarily use. In the 48-week MASLD Phase 2a trial, retatrutide 12 mg reduced liver fat by −82.4% at 24 weeks, with 86% of participants reaching normal liver fat (<5%) — a result attributed in the mechanistic literature specifically to the glucagon arm's hepatic action [5, 7]. A 2025 mechanistic review confirmed that glucagon receptor agonism in multi-agonist designs drives improved liver health via hepatic lipolysis stimulation, mitochondrial fat oxidation, reduced caloric intake, and increased energy expenditure — working in parallel on the same target organ [7]. Retatrutide's relative potency at GCGR is approximately 0.3× native glucagon [3], a deliberately subdued level. Full glucagon activation would raise blood glucose — counterproductive in a metabolic compound — so the potency is calibrated to achieve hepatic fat oxidation and thermogenic benefit while avoiding glucose elevation. The dose-dependent heart-rate increase observed in Phase 2 (mean ~5–7 bpm at highest doses) is also a glucagon receptor effect: glucagon drives cardiac chronotropy (speeding the heart rate) via cAMP/PKA signaling. ## Structural confirmation: cryo-EM at three receptors The structural pharmacology of how retatrutide works was confirmed in a 2024 cryo-EM study published in *Cell Discovery* [3]. Cryo-electron microscopy (cryo-EM) is a technique that freezes protein complexes and uses electron beams to resolve their three-dimensional structure at near-atomic resolution. The study resolved retatrutide bound to all three receptor complexes: at 2.68 Å (GLP-1R), 3.26 Å (GIPR), and 2.84 Å (GCGR). A key structural finding was how the ECL1 (extracellular loop 1) of each receptor adapts to retatrutide: it adopts a rigid alpha-helix (stable spiral structure) in GLP-1R and GCGR, but a flexible loop in GIPR — a conformational difference that contributes to the differential potency profile and explains aspects of the receptor selectivity. The relative potencies measured in cAMP signaling assays — 8.9× at GIPR, 0.3× at GCGR, 0.4× at GLP-1R versus native hormones — are not accidental. They reflect deliberate engineering choices in the C20 fatty-diacid acylated, GIP-backbone-based peptide structure that produced the specific binding geometry confirmed in the cryo-EM structures [3]. For comparative mechanism context, see [Retatrutide research](/research) and [retatrutide results](/results). --- An independent appraisal of the published retatrutide trial record — each figure traced to its study, the Phase 3 questions held open, nothing here prescribed or dispensed.